Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02115295 · ClinicalTrials.gov registry record · Phase 2

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

A Phase 2 study of Acute Myeloid Leukemia and Myelodysplastic Syndrome, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
508
Enrollment target
1
Study location

NCT02115295 is a Phase 2 study of Acute Myeloid Leukemia and Myelodysplastic Syndrome that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 508 participants, above the 114-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (346% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02115295, a Phase 2 study of Acute Myeloid Leukemia and Myelodysplastic Syndrome, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
508 participants
Enrollment target
1
Study location

Study Summary

This phase II trial studies how well cladribine, idarubicin, cytarabine, and venetoclax work in patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blastic phase chronic myeloid leukemia. Drugs used in chemotherapy, such as cladribine, idarubicin, cytarabine, and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Conditions Studied

Acute Myeloid Leukemia Myelodysplastic Syndrome Recurrent Acute Myeloid Leukemia Acute Biphenotypic Leukemia Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Previously Treated Myelodysplastic Syndrome de Novo Myelodysplastic Syndrome Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive Blasts 10 Percent or More of Bone Marrow Nucleated Cells Blasts 10 Percent or More of Peripheral Blood White Cells

Interventions

  • DRUG Cladribine
  • OTHER Laboratory Biomarker Analysis
  • DRUG Cytarabine
  • DRUG Idarubicin
  • DRUG Gilteritinib

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 508 participants
Start Date 2014-05-19
Est. Completion 2030-05-31
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02115295

The ClinicalTrials.gov registry entry for NCT02115295 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 508 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 114-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (346% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Cladribine is the first listed.

NCT02115295 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02115295 about?

NCT02115295 is a clinical study titled "Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia". This phase II trial studies how well cladribine, idarubicin, cytarabine, and venetoclax work in patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blastic phase chronic myeloid leukemia. Drugs used in chemotherapy, such as cladribine, idarubicin, cytarabine, and venetoclax,...

What is the current status of trial NCT02115295?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 508 participants. The study started on 2014-05-19. Estimated completion is 2030-05-31.

What conditions does trial NCT02115295 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Acute Biphenotypic Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive.

What interventions are being tested in trial NCT02115295?

The interventions under investigation include: Cladribine (DRUG), Laboratory Biomarker Analysis (OTHER), Cytarabine (DRUG), Idarubicin (DRUG), Gilteritinib (DRUG).

Who is sponsoring clinical trial NCT02115295?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02115295 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia

All registered trials for this condition

Myelodysplastic Syndrome

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.